1. |
Rojo LE, Gaspar PA, Silva H,et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res, 2015, 101: 74-85.
|
2. |
Jesus C, Jesus I, Agius M. A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. Psychiatr Danub, 2015, 27(Suppl 1): 489-491.
|
3. |
Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet, 2005, 365(9465): 1163-1174.
|
4. |
Cohen AT, Dobromiski M, Gurwith MM. Managing pulmonary embolism from presentation to extended treatment. Thromb Res, 2014, 133(2): 139-148.
|
5. |
Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet, 2012, 379(9828): 1835-1846.
|
6. |
Maurice H. Des complications phlepitiques au cours des traitements par les neuroleptiques. Encephale, 1956, 45(4): 797-801.
|
7. |
Grahmann H, Suchenwirth R. Thrombose hazard in chlorpromazine and reserpine therapy of endogenous psychosis. Nervenazt, 1959, 30(5): 224-225.
|
8. |
Mahmodian M. Ursachen der lungenembolie bei psychisch und neurologisch Kranken. Rrch Psichiatr Nervenkr, 1963, 204: 229-244.
|
9. |
Meier-Ewert K, Baumgart H, Friedenberg P. Thromboembolism complications in neuro- and thymoleptic therapy. Dtsch Med Wochenschr, 1967, 92(47): 2174-2178.
|
10. |
Walker AM, Lanza LL, Arellano F,et al. Mortality in current and former users of clozapine. Epidemiology, 1997, 8(6): 671-677.
|
11. |
Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet, 2000, 355(9210): S1155-S1156.
|
12. |
王建秋, 刘广敬, 路以荣. 精神分裂症合并肺栓塞一例. 中华精神科杂志, 2006, 39(3): 140.
|
13. |
刘人申, 汪作为, 张少平. 氯氮平致肺栓塞 1 例. 临床精神医学杂志, 2007, 17(1): 64.
|
14. |
Zhang R, Dong L, Shao F,et al. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry, 2011, 44(5): 183-188.
|
15. |
Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf, 2014, 37(2): 79-90.
|
16. |
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev, 1987, 9(1): 1-30.
|
17. |
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
|
18. |
Wu CS, Lin CC, Chang CM,et al. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J Chin Psychiatry, 2013, 74(9): 918-924.
|
19. |
Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. J Clin Psychopharmacol, 2013, 33(6): 753-758.
|
20. |
Ishiguro C, Wang X, Li L,et al. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD. Pharmacoepidemiol Drug Saf, 2014, 23(11): 1168-1175.
|
21. |
Wang MT, Liou JT, Huang YW ,et al. Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. Thromb Haemost, 2016, 115(6): 1209-1219.
|
22. |
Masopust J, Maly R, Urban A,et al. Antipsychotic drugs as a risk factor for venous thromboembolism. Int J Psych Clin Pract, 2007, 11(3): 246-249.
|
23. |
Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet, 2000, 356(9237): 1219-1223.
|
24. |
Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry, 2001, 179: 63-66.
|
25. |
Liperoti R, Pedone C, Lapane KL,et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med, 2005, 165(22): 2677-2682.
|
26. |
Lacut K, Le GG, Couturaud F,et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol, 2007, 21(6): 643-650.
|
27. |
Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case–control study. BMJ, 2010, 341: c4245.
|
28. |
Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ, 2011, 343: d4656.
|
29. |
Jonsson AK, Horvath-Puho E, Hagg S,et al. Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol, 2009, 1(9): 19-26.
|
30. |
Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost, 2002, 88(2): 205-209.
|
31. |
Kleijer BC, Heerdink ER, Egberts TC,et al. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol, 2010, 30(5): 526-530.
|
32. |
Allenet B, Schmidlin S, Genty C,et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf, 2012, 21(1): 42-48.
|
33. |
Conti Valentino, Venegoni Manro, Cocci Alfredo,et al. Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control study. BMC Psychiatry, 2015, 1592.
|
34. |
Hamanaka S, Kamijo Y, Nagai T,et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J, 2004, 68(9): 850-852.
|
35. |
Parkin L, Skegg DC, Herbison GP,et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf, 2003, 12(8): 647-652.
|
36. |
Jonsson AK, Brudin L, Ahlner J,et al. Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. Int Clin Psychopharmacol, 2008, 23(5): 263-268.
|
37. |
Kamijo Y, Soma K, Nagai T,et al. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J, 2003, 67(4): 46-48.
|
38. |
Skokou M, Gourzis P. Pulmonary embolism related to amisulpride treatment: a case report. Case Rep Psychiatry, 2013, 2013: 718950.
|
39. |
Jönsson AK, Spigset O, Hagg S. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs, 2012, 26(8): 649-662.
|
40. |
Hagg S, Jonsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Drug Saf, 2009, 8(5): 537-547.
|
41. |
Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs, 2002, 16(11): 765-776.
|